Lunai Bioworks Inc
Research Lunai Bioworks Inc (LNAI) on Bullrun: market cap USD 9.97M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLNAI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 9.97M
- Financial periodQ1 2026
- RevenueUSD 20.94K
- Net income-USD 2.57M
- Free cash flow-USD 1.03M
- Gross margin100.0%
Valuation Snapshot
latest market cap is USD 9.97M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 178.01M | -USD 5.72M | n/a | -1.08 | USD 92.70K | USD 2.75M | -USD 21.35M |
| FY2024 | n/a | -USD 88.43M | -USD 11.04M | n/a | -0.91 | USD 220.47K | USD 6.37M | USD 131.98M |
| FY2023 | n/a | -USD 39.68M | -USD 11.80M | n/a | -0.71 | USD 1.87M | n/a | USD 46.50M |
| FY2022 | n/a | -USD 113.43M | -USD 15.74M | n/a | -2.16 | USD 9.17M | n/a | USD 72.62M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 9.97M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 20.40M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 135.55M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 213.10M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 57.17M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 383.69M | n/a | n/a | n/a |
About Lunai Bioworks Inc
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Lunai Bioworks Inc's market cap?
Lunai Bioworks Inc's market capitalization is USD 9.97M.
What does Lunai Bioworks Inc do?
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.